{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:05:20Z","timestamp":1790129120916,"version":"4.0.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Numerous vaccination research experiments have been conducted on non-primate hosts to prevent or control HTLV-1 infection. Therefore, reviewing recent advancements for status assessment and strategic planning of future preventative actions to reduce HTLV-1 infection and its consequences would be essential.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>MEDLINE, Scopus, Web of Science, and Clinicaltrials.gov were searched from each database's inception through March 27, 2022. All original articles focusing on developing an HTLV-1 vaccine candidate were included.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 47 studies were included. They used a variety of approaches to develop the HTLV-1 vaccine, including DNA-based, dendritic-cell-based, peptide\/protein-based, and recombinant vaccinia virus approaches. The majority of the research that was included utilized Tax, Glycoprotein (GP), GAG, POL, REX, and HBZ as their main peptides in order to develop the vaccine. The immunization used in dendritic cell-based investigations, which were more recently published, was accomplished by an activated CD-8\u00a0T-cell response. Although there hasn't been much attention lately on this form of the vaccine, the initial attempts to develop an HTLV-1 immunization depended on recombinant vaccinia virus, and the majority of results seem positive and effective for this type of vaccine. Few studies were conducted on humans. Most of the studies were experimental studies using animal models. Adenovirus, Cytomegalovirus (CMV), vaccinia, baculovirus, hepatitis B, measles, and pox were the most commonly used vectors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This systematic review reported recent progression in the development of HTLV-1 vaccines to identify candidates with the most promising preventive and therapeutic effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08289-7","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T11:03:31Z","timestamp":1683803011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies"],"prefix":"10.1186","volume":"23","author":[{"given":"Niloofar","family":"Seighali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Shafiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Rafiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dlnya","family":"Aminzade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4570-2252","authenticated-orcid":false,"given":"Sayed-Hamidreza","family":"Mozhgani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"issue":"1","key":"8289_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.virol.2012.09.028","volume":"435","author":"LB Cook","year":"2013","unstructured":"Cook LB, Elemans M, Rowan AG, Asquith BJV. HTLV-1: persistence and pathogenesis. Virology. 2013;435(1):131\u201340.","journal-title":"Virology"},{"issue":"8","key":"8289_CR2","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood-2009-12-257410","volume":"116","author":"M Iwanaga","year":"2010","unstructured":"Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh K-R, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116(8):1211\u20139.","journal-title":"Blood"},{"key":"8289_CR3","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","volume":"3","author":"A Gessain","year":"2012","unstructured":"Gessain A, Cassar O. Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol. 2012;3:388.","journal-title":"Front Microbiol"},{"key":"8289_CR4","doi-asserted-by":"crossref","unstructured":"Gessain A, Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection.\u00a0Front Microbiol. 2012;3.","DOI":"10.3389\/fmicb.2012.00388"},{"issue":"39","key":"8289_CR5","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.1038\/sj.onc.1208968","volume":"24","author":"FA Proietti","year":"2005","unstructured":"Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy ELJO. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24(39):6058\u201368.","journal-title":"Oncogene"},{"issue":"5","key":"8289_CR6","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s12185-011-0934-4","volume":"94","author":"T Watanabe","year":"2011","unstructured":"Watanabe T. Current status of HTLV-1 infection. Int J Hematol. 2011;94(5):430\u20134.","journal-title":"Int J Hematol"},{"issue":"3","key":"8289_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0925-5710(97)00077-7","volume":"66","author":"T Watanabe","year":"1997","unstructured":"Watanabe T. HTLV-1-associated diseases. Int J Hematol. 1997;66(3):257\u201378.","journal-title":"Int J Hematol"},{"issue":"1","key":"8289_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1473-3099(19)30402-5","volume":"20","author":"G Schierhout","year":"2020","unstructured":"Schierhout G, McGregor S, Gessain A, Einsiedel L, Martinello M, Kaldor JJTLID. Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies. Lancet Infect Dis. 2020;20(1):133\u201343.","journal-title":"Lancet Infect Dis"},{"key":"8289_CR9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3389\/fmicb.2012.00322","volume":"3","author":"M Iwanaga","year":"2012","unstructured":"Iwanaga M, Watanabe T, Yamaguchi K. Adult T-cell leukemia: a review of epidemiological evidence. Front Microbiol. 2012;3:322.","journal-title":"Front Microbiol"},{"issue":"11","key":"8289_CR10","doi-asserted-by":"publisher","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","volume":"15","author":"K Ishitsuka","year":"2014","unstructured":"Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma Lancet Oncol. Lancet Oncol. 2014;15(11):e517\u201326.","journal-title":"Lancet Oncol"},{"issue":"1","key":"8289_CR11","doi-asserted-by":"publisher","first-page":"15012","DOI":"10.1038\/nrdp.2015.12","volume":"1","author":"CRM Bangham","year":"2015","unstructured":"Bangham CRM, Araujo A, Yamano Y, Taylor GP. HTLV-1-associated myelopathy\/tropical spastic paraparesis. Nat Rev Dis Primers. 2015;1(1):15012.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"8289_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2174\/187152808785107642","volume":"7","author":"DU Goncalves","year":"2008","unstructured":"Goncalves DU, Proietti FA, Barbosa-Stancioli EF, Martins ML, Ribas JG, Martins-Filho OA, et al. HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) inflammatory network. Inflamm Allergy Drug Targets. 2008;7(2):98\u2013107.","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"1\u20132","key":"8289_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jns.2005.05.010","volume":"237","author":"S Olindo","year":"2005","unstructured":"Olindo S, L\u00e9zin A, Cabre P, Merle H, Saint-Vil M, Kaptue ME, et al. HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM\/TSP patients: a marker of disease progression. J Neurol Sci. 2005;237(1\u20132):53\u20139.","journal-title":"J Neurol Sci"},{"issue":"7","key":"8289_CR14","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/jmv.22087","volume":"83","author":"MFR Grassi","year":"2011","unstructured":"Grassi MFR, Olavarria VN, Kruschewsky RDA, Mascarenhas RE, Dourado I, Correia LC, et al. Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) patients according to new diagnostic criteria of HAM\/TSP. J Med Virol. 2011;83(7):1269\u201374.","journal-title":"J Med Virol"},{"issue":"3","key":"8289_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/v8030074","volume":"8","author":"C Gross","year":"2016","unstructured":"Gross C, Thoma-Kress AKJV. Molecular mechanisms of HTLV-1 cell-to-cell transmission. Viruses. 2016;8(3):74.","journal-title":"Viruses"},{"issue":"14","key":"8289_CR16","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.1128\/JVI.02719-05","volume":"80","author":"D Ghez","year":"2006","unstructured":"Ghez D, Lepelletier Y, Lambert S, Fourneau J-M, Blot V, Janvier S, et al. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry. J Virol. 2006;80(14):6844\u201354.","journal-title":"J Virol"},{"issue":"21","key":"8289_CR17","first-page":"5176","volume":"113","author":"S Lambert","year":"2009","unstructured":"Lambert S, Bouttier M, Vassy R, Seigneuret M, Petrow-Sadowski C, Janvier S, et al. HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165. Boold. 2009;113(21):5176\u201385.","journal-title":"Boold"},{"issue":"4","key":"8289_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0092-8674(03)00881-X","volume":"115","author":"N Manel","year":"2003","unstructured":"Manel N, Kim FJ, Kinet S, Taylor N, Sitbon M, Battini J-LJC. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell. 2003;115(4):449\u201359.","journal-title":"Cell"},{"issue":"1","key":"8289_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1742-4690-4-31","volume":"4","author":"S Kinet","year":"2007","unstructured":"Kinet S, Swainson L, Lavanya M, Mongellaz C, Montel-Hagen A, Craveiro M, et al. Isolated receptor binding domains of HTLV-1 and HTLV-2 envelopes bind Glut-1 on activated CD4+ and CD8+ T cells. Retrovirology. 2007;4(1):31.","journal-title":"Retrovirology"},{"issue":"1732","key":"8289_CR20","doi-asserted-by":"publisher","first-page":"20160272","DOI":"10.1098\/rstb.2016.0272","volume":"372","author":"CR Bangham","year":"2017","unstructured":"Bangham CR, Matsuoka M. Human T-cell leukaemia virus type 1: parasitism and pathogenesis. Philos Trans R Soc Lond B Biol Sci. 2017;372(1732):20160272.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"12","key":"8289_CR21","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","volume":"77","author":"BJ Poiesz","year":"1980","unstructured":"Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980;77(12):7415\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8289_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.antiviral.2016.10.015","volume":"137","author":"L Willems","year":"2017","unstructured":"Willems L, Hasegawa H, Accolla R, Bangham C, Bazarbachi A, Bertazzoni U, et al. Reducing the global burden of HTLV-1 infection: an agenda for research and action. Antiviral Res. 2017;137:41\u20138.","journal-title":"Antiviral Res"},{"issue":"10133","key":"8289_CR23","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/S0140-6736(18)30974-7","volume":"391","author":"F Martin","year":"2018","unstructured":"Martin F, Tagaya Y, Gallo RJTL. Time to eradicate HTLV-1: an open letter to WHO. Lancet. 2018;391(10133):1893\u20134.","journal-title":"Lancet"},{"key":"8289_CR24","doi-asserted-by":"crossref","unstructured":"Gallo RC, Willems L, Hasegawa H, the Global Virus Network\u2019s Task Force on H. Screening transplant donors for HTLV-1 and -2. Blood. 2016;128(26):3029\u201331.","DOI":"10.1182\/blood-2016-09-739433"},{"key":"8289_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.5581\/1516-8484.20140013","volume":"36","author":"GMDC Viana","year":"2014","unstructured":"Viana GMDC, Nascimento MDDSB, Oliveira RASD, Santos ACD, Galvao CD, Silva MACN. Seroprevalence of HTLV-1\/2 among blood donors in the state of Maranh\u00e3o, Brazil. Rev Bras Hematol Hemoter. 2014;36:50\u20133.","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"1","key":"8289_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1046\/j.1537-2995.1989.29189101168.x","volume":"29","author":"S Inaba","year":"1989","unstructured":"Inaba S, Sato H, Okochi K, Fukada K, Takakura F, Tokunaga K, et al. Prevention of transmission of human T-lymphotropic virus type 1 (HTLV-1) through transfusion, by donor screening with antibody to the virus One-year experience. Transfusion. 1989;29(1):7\u201311.","journal-title":"Transfusion"},{"issue":"11","key":"8289_CR27","doi-asserted-by":"publisher","first-page":"e0006913","DOI":"10.1371\/journal.pntd.0006913","volume":"12","author":"C Rosadas","year":"2018","unstructured":"Rosadas C, Malik B, Taylor GP, Puccioni-Sohler M. Estimation of HTLV-1 vertical transmission cases in Brazil per annum. PLoS Negl Trop Dis. 2018;12(11):e0006913.","journal-title":"PLoS Negl Trop Dis"},{"key":"8289_CR28","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3389\/fmicb.2019.00999","volume":"10","author":"C Rosadas","year":"2019","unstructured":"Rosadas C, Taylor GP. Mother-to-child HTLV-1 transmission: unmet research needs. Front Microbiol. 2019;10:999.","journal-title":"Front Microbiol"},{"issue":"4","key":"8289_CR29","doi-asserted-by":"publisher","first-page":"20180051","DOI":"10.1515\/jib-2018-0051","volume":"16","author":"S Alam","year":"2020","unstructured":"Alam S, Hasan MK, Manjur OHB, Khan AM, Sharmin Z, Pavel MA, et al. Predicting and Designing Epitope Ensemble Vaccines against HTLV-1. J Integr Bioinform. 2020;16(4):20180051.","journal-title":"J Integr Bioinform"},{"key":"8289_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.micpath.2016.05.012","volume":"97","author":"M Amirnasr","year":"2016","unstructured":"Amirnasr M, Fallah Tafti T, Sankian M, Rezaei A, Tafaghodi M. Immunization against HTLV-I with chitosan and tri-methylchitosan nanoparticles loaded with recombinant env23 and env13 antigens of envelope protein gp46. Microb Pathog. 2016;97:38\u201344.","journal-title":"Microb Pathog"},{"issue":"3","key":"8289_CR31","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.4049\/jimmunol.1601557","volume":"198","author":"S Ando","year":"2017","unstructured":"Ando S, Hasegawa A, Murakami Y, Zeng N, Takatsuka N, Maeda Y, et al. HTLV-1 Tax-specific CTL epitope-pulsed dendritic cell therapy reduces proviral load in infected rats with immune tolerance against tax. J Immunol. 2017;198(3):1210\u20139.","journal-title":"J Immunol"},{"issue":"21","key":"8289_CR32","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0264-410X(99)00565-4","volume":"18","author":"MA Armand","year":"2000","unstructured":"Armand MA, Grange MP, Paulin D, Desgranges C. Targeted expression of HTLV-I envelope proteins in muscle by DNA immunization of mice. Vaccine. 2000;18(21):2212\u201322.","journal-title":"Vaccine"},{"issue":"2","key":"8289_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1099\/0022-1317-74-2-211","volume":"74","author":"J Arp","year":"1993","unstructured":"Arp J, Ford CM, Palker TJ, King EE, Dekaban GA. Expression and immunogenicity of the entire human T cell leukaemia virus type I envelope protein produced in a baculovirus system. J Gen Virol. 1993;74(2):211\u201322.","journal-title":"J Gen Virol"},{"issue":"11","key":"8289_CR34","doi-asserted-by":"publisher","first-page":"7349","DOI":"10.1128\/jvi.70.11.7349-7359.1996","volume":"70","author":"J Arp","year":"1996","unstructured":"Arp J, Levatte M, Rowe J, Perkins S, King E, Leystra-Lantz C, et al. A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: Expression of gp46 by the vaccinia virus\/T7 polymerase system. J Virol. 1996;70(11):7349\u201359.","journal-title":"J Virol"},{"issue":"1","key":"8289_CR35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.4049\/jimmunol.154.1.399","volume":"154","author":"E Baba","year":"1995","unstructured":"Baba E, Nakamura M, Ohkuma K, Kira JI, Tanaka Y, Nakano S, et al. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies. J Immunol. 1995;154(1):399\u2013412.","journal-title":"J Immunol"},{"issue":"1","key":"8289_CR36","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/0042-6822(92)90208-7","volume":"191","author":"CM Ford","year":"1992","unstructured":"Ford CM, Arp J, Palker TJ, King EE, Dekaban GA. Characterization of the antibody response to three different versions of the HTLV-I envelope protein expressed by recombinant vaccinia viruses: Induction of neutralizing antibody. Virology. 1992;191(1):448\u201353.","journal-title":"Virology"},{"issue":"2","key":"8289_CR37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1089\/aid.1995.11.307","volume":"11","author":"G Franchini","year":"1995","unstructured":"Franchini G, Tartaglia J, Markham P, Benson J, Fullen J, Wills M, et al. Highly Attenuated HTLV Type Ienv Poxvirus Vaccines Induce Protection against a Cell-Associated HTLV Type I Challenge in Rabbits. AIDS Res Hum Retroviruses. 1995;11(2):307\u201313.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"9\u201310","key":"8289_CR38","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S0264-410X(00)00340-6","volume":"19","author":"M Frangione-Beebe","year":"2000","unstructured":"Frangione-Beebe M, Albrecht B, Dakappagari N, Rose RT, Brooks CL, Schwendeman SP, et al. Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide. Vaccine. 2000;19(9\u201310):1068\u201381.","journal-title":"Vaccine"},{"issue":"5","key":"8289_CR39","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/02652040110055216","volume":"18","author":"M Frangione-Beebe","year":"2001","unstructured":"Frangione-Beebe M, Rose RT, Kaumaya PTP, Schwendeman SP. Microencapsulation of a synthetic peptide epitope for HTLV-1 in biodegradable poly(D, L-lactide-co-glycolide) microspheres using a novel encapsulation technique. J Microencapsul. 2001;18(5):663\u201377.","journal-title":"J Microencapsul"},{"issue":"2","key":"8289_CR40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/v8020041","volume":"8","author":"H Fujii","year":"2016","unstructured":"Fujii H, Shimizu M, Miyagi T, Kunihiro M, Tanaka R, Takahashi Y, et al. A potential of an Anti-HTLV-I gp46 neutralizing monoclonal antibody (LAT-27) for passive immunization against both horizontal and mother-to-child vertical infection with human T cell leukemia virus type-I. Viruses. 2016;8(2):41.","journal-title":"Viruses"},{"key":"8289_CR41","doi-asserted-by":"crossref","unstructured":"Fujisawa J-i, Lee S-i, Yao J, Ren Y, Tanaka M. Tax peptide vaccine suppressed the leukemia in humanized mouse model of ATL. Retrovirology. 2015;12(1):O43.","DOI":"10.1186\/1742-4690-12-S1-O43"},{"issue":"12","key":"8289_CR42","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1089\/dna.1997.16.1439","volume":"16","author":"MP Grange","year":"1997","unstructured":"Grange MP, Armand MA, Audoly G, Thollot D, Desgranges C. Induction of neutralizing antibodies against HTLV-I envelope proteins after combined genetic and protein immunizations in mice. DNA Cell Biol. 1997;16(12):1439\u201348.","journal-title":"DNA Cell Biol"},{"issue":"4","key":"8289_CR43","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/ijc.2910600423","volume":"60","author":"E Hakoda","year":"1995","unstructured":"Hakoda E, Machida H, Tanaka Y, Morishita N, Sawada T, Shida H, et al. Vaccination of rabbits with recombinant vaccinia virus carrying the envelope gene of human T-cell lymphotropic virus type I. Int J Cancer. 1995;60(4):567\u201370.","journal-title":"Int J Cancer"},{"issue":"23","key":"8289_CR44","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1093\/jnci\/93.23.1775","volume":"93","author":"S Hanabuchi","year":"2001","unstructured":"Hanabuchi S, Ohashi T, Koya Y, Kato H, Hasegawa A, Takemura F, et al. Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in a rat model: Peptide-induced T-cell immunity. J Natl Cancer Inst. 2001;93(23):1775\u201383.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"8289_CR45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1099\/0022-1317-78-1-147","volume":"78","author":"K Ibuki","year":"1997","unstructured":"Ibuki K, Funahashi SI, Yamamoto H, Nakamura M, Igarashi T, Miura T, et al. Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human T cell leukaemia virus type I envelope gene. J Gen Virol. 1997;78(1):147\u201352.","journal-title":"J Gen Virol"},{"issue":"3","key":"8289_CR46","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/cas.14800","volume":"112","author":"M Ishizawa","year":"2021","unstructured":"Ishizawa M, Ganbaatar U, Hasegawa A, Takatsuka N, Kondo N, Yoneda T, et al. Short-term cultured autologous peripheral blood mononuclear cells as a potential immunogen to activate Tax-specific CTL response in adult T-cell leukemia patients. Cancer Sci. 2021;112(3):1161\u201372.","journal-title":"Cancer Sci"},{"issue":"15","key":"8289_CR47","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.1080\/07391102.2021.1889669","volume":"40","author":"HR Jahantigh","year":"2022","unstructured":"Jahantigh HR, Stufano A, Lovreglio P, Rezaee SA, Ahmadi K. In silico identification of epitope-based vaccine candidates against HTLV-1. J Biomol Struct Dyn. 2022;40(15):6737\u201354.","journal-title":"J Biomol Struct Dyn"},{"issue":"1\u20132","key":"8289_CR48","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ijpharm.2018.07.069","volume":"549","author":"M Kabiri","year":"2018","unstructured":"Kabiri M, Sankian M, Hosseinpour M, Tafaghodi M. The novel immunogenic chimeric peptide vaccine to elicit potent cellular and mucosal immune responses against HTLV-1. Int J Pharm. 2018;549(1\u20132):404\u201314.","journal-title":"Int J Pharm"},{"key":"8289_CR49","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ejpb.2018.11.003","volume":"133","author":"M Kabiri","year":"2018","unstructured":"Kabiri M, Sankian M, Sadri K, Tafaghodi M. Robust mucosal and systemic responses against HTLV-1 by delivery of multi-epitope vaccine in PLGA nanoparticles. Eur J Pharm Biopharm. 2018;133:321\u201330.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"8289_CR50","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/(SICI)1097-0215(19970410)71:2<300::AID-IJC27>3.0.CO;2-J","volume":"71","author":"M Kazanji","year":"1997","unstructured":"Kazanji M, Bomford R, Bessereau JL, Schulz T, De Th\u00e9 G. Expression and immunogenicity in rats of recombinant adenovirus 5 DNA plasmids and vaccinia virus containing the HTLV-I env gene. Int J Cancer. 1997;71(2):300\u20137.","journal-title":"Int J Cancer"},{"key":"8289_CR51","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1099\/vir.0.81582-0","volume":"87","author":"M Kazanji","year":"2006","unstructured":"Kazanji M, Heraud JM, Merien F, Pique C, de The G, Gessain A, et al. Chimeric peptide vaccine composed of B- and T-cell epitopes of human T-cell leukemia virus type 1 induces humoral and cellular immune responses and reduces the proviral load in immunized squirrel monkeys (Saimiri sciureus). J Gen Virol. 2006;87:1331\u20137.","journal-title":"J Gen Virol"},{"issue":"13","key":"8289_CR52","doi-asserted-by":"publisher","first-page":"5939","DOI":"10.1128\/JVI.75.13.5939-5948.2001","volume":"75","author":"M Kazanji","year":"2001","unstructured":"Kazanji M, Tartaglia J, Franchini G, de Thoisy B, Talarmin A, Contamin H, et al. Immunogenicity and protective efficacy of recombinant human T-cell leukemia\/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus). J Virol. 2001;75(13):5939\u201348.","journal-title":"J Virol"},{"issue":"12","key":"8289_CR53","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s00262-012-1284-7","volume":"61","author":"H Kobayashi","year":"2012","unstructured":"Kobayashi H, Kumai T, Hayashi S, Matsuda Y, Aoki N, Sato K, et al. A naturally processed HLA-DR-bound peptide from the IL-9 receptor alpha of HTLV-1-transformed T cells serves as a T helper epitope. Cancer Immunol Immunother. 2012;61(12):2215\u201325.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"8289_CR54","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1158\/1078-0432.CCR-06-0384","volume":"12","author":"H Kobayashi","year":"2006","unstructured":"Kobayashi H, Ngato T, Sato K, Aoki N, Kimura S, Tanaka Y, et al. In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes. Clin Cancer Res. 2006;12(12):3814\u201322.","journal-title":"Clin Cancer Res"},{"issue":"2\u20133","key":"8289_CR55","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.molimm.2009.09.006","volume":"47","author":"T Kozako","year":"2009","unstructured":"Kozako T, Fukada K, Hirata S, White Y, Harao M, Nishimura Y, et al. Efficient induction of human T-cell leukemia virus-1-specific CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia. Mol Immunol. 2009;47(2\u20133):606\u201313.","journal-title":"Mol Immunol"},{"issue":"8","key":"8289_CR56","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/j.1742-4658.2011.08055.x","volume":"278","author":"T Kozako","year":"2011","unstructured":"Kozako T, Hirata S, Shimizu Y, Satoh Y, Yoshimitsu M, White Y, et al. Oligomannose-coated liposomes efficiently induce human T-cell leukemia virus-1-specific cytotoxic T lymphocytes without adjuvant. FEBS J. 2011;278(8):1358\u201366.","journal-title":"FEBS J"},{"issue":"1","key":"8289_CR57","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4049\/jimmunol.1100070","volume":"187","author":"CW Kuo","year":"2011","unstructured":"Kuo CW, Mirsaliotis A, Brighty DW. Antibodies to the envelope glycoprotein of human T cell leukemia virus type 1 robustly activate cell-mediated cytotoxic responses and directly neutralize viral infectivity at multiple steps of the entry process. J Immunol (Baltimore, Md\u202f: 1950). 2011;187(1):361\u201371.","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"issue":"10","key":"8289_CR58","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1128\/jvi.69.10.6077-6089.1995","volume":"69","author":"MD Lairmore","year":"1995","unstructured":"Lairmore MD, DiGeorge AM, Conrad SF, Trevino AV, Lal RB, Kaumaya PT. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction. J Virol. 1995;69(10):6077\u201389.","journal-title":"J Virol"},{"issue":"8","key":"8289_CR59","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3390\/v13081461","volume":"13","author":"G Lucchese","year":"2021","unstructured":"Lucchese G, Jahantigh HR, De Benedictis L, Lovreglio P, Stufano A. An epitope platform for safe and effective HTLV-1-immunization: Potential applications for mRNA and peptide-based vaccines. Viruses. 2021;13(8):1461.","journal-title":"Viruses"},{"issue":"33","key":"8289_CR60","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1016\/j.vaccine.2018.07.002","volume":"36","author":"R Mulherkar","year":"2018","unstructured":"Mulherkar R, Karabudak A, Ginwala R, Huang X, Rowan A, Philip R, et al. In vivo and in vitro immunogenicity of novel MHC class I presented epitopes to confer protective immunity against chronic HTLV-1 infection. Vaccine. 2018;36(33):5046\u201357.","journal-title":"Vaccine"},{"issue":"3","key":"8289_CR61","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ijc.2910400320","volume":"40","author":"H Nakamura","year":"1987","unstructured":"Nakamura H, Hayami M, Ohta Y, Ishikawa KI, Tsujimoto H, Kiyokawa T, et al. Protection of cynomolgus monkeys against infection by human T-cell leukemia virus type-I by immunization with viral env gene products produced in Escherichia coli. Int J Cancer. 1987;40(3):403\u20137.","journal-title":"Int J Cancer"},{"issue":"20","key":"8289_CR62","doi-asserted-by":"publisher","first-page":"9610","DOI":"10.1128\/JVI.74.20.9610-9616.2000","volume":"74","author":"T Ohashi","year":"2000","unstructured":"Ohashi T, Hanabuchi S, Kato H, Tateno H, Takemura F, Tsukahara T, et al. Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA vaccine. J Virol. 2000;74(20):9610\u20136.","journal-title":"J Virol"},{"issue":"6","key":"8289_CR63","doi-asserted-by":"publisher","first-page":"8717","DOI":"10.1002\/jcp.27531","volume":"234","author":"RK Pandey","year":"2019","unstructured":"Pandey RK, Ojha R, Chatterjee N, Upadhyay N, Mishra A, Prajapati VK. Combinatorial screening algorithm to engineer multiepitope subunit vaccine targeting human T-lymphotropic virus-1 infection. J Cell Physiol. 2019;234(6):8717\u201326.","journal-title":"J Cell Physiol"},{"issue":"4 April","key":"8289_CR64","doi-asserted-by":"publisher","first-page":"e0248001","DOI":"10.1371\/journal.pone.0248001","volume":"16","author":"MT Raza","year":"2021","unstructured":"Raza MT, Mizan S, Yasmin F, Akash AS, Shahik SM. Epitope-based universal vaccine for Human T-lymphotropic virus-1 (HTLV-1). PLoS One. 2021;16(4 April):e0248001.","journal-title":"PLoS One"},{"issue":"26","key":"8289_CR65","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.1016\/j.vaccine.2014.03.087","volume":"32","author":"D Sagar","year":"2014","unstructured":"Sagar D, Masih S, Schell T, Jacobson S, Comber JD, Philip R, et al. In vivo immunogenicity of Tax (11\u201319) epitope in HLA-A2\/DTR transgenic mice: Implication for dendritic cell-based anti-HTLV-1 vaccine. Vaccine. 2014;32(26):3274\u201384.","journal-title":"Vaccine"},{"issue":"1","key":"8289_CR66","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1006\/viro.1996.0632","volume":"226","author":"C Sch\u00f6nbach","year":"1996","unstructured":"Sch\u00f6nbach C, Nokihara K, Bangham CR, Kariyone A, Karaki S, Shida H, et al. Identification of HTLV-1-specific CTL directed against synthetic and naturally processed peptides in HLA-B* 3501 transgenic mice. Virology. 1996;226(1):102\u201312.","journal-title":"Virology"},{"key":"8289_CR67","doi-asserted-by":"publisher","first-page":"120920","DOI":"10.1016\/j.lfs.2022.120920","volume":"308","author":"M Shafifar","year":"2022","unstructured":"Shafifar M, Mozhgani SH, Razavi Pashabayg K, Mosavat A, Karbalaei M, Norouzi M, et al. Selective APC-targeting of a novel Fc-fusion multi-immunodominant recombinant protein ((t)Tax-(t)Env:mFc\u03b32a) for HTLV-1 vaccine development. Life Sci. 2022;308:120920.","journal-title":"Life Sci"},{"issue":"12","key":"8289_CR68","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.1128\/jvi.62.12.4474-4480.1988","volume":"62","author":"H Shida","year":"1988","unstructured":"Shida H, Hinuma Y, Hatanaka M, Morita M, Kidokoro M, Suzuki K, et al. Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene. J Virol. 1988;62(12):4474\u201380.","journal-title":"J Virol"},{"issue":"11","key":"8289_CR69","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1002\/j.1460-2075.1987.tb02660.x","volume":"6","author":"H Shida","year":"1987","unstructured":"Shida H, Tochikura T, Sato T, Konno T, Hirayoshi K, Seki M, et al. Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection. EMBO J. 1987;6(11):3379\u201384.","journal-title":"EMBO J"},{"issue":"3","key":"8289_CR70","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/bjh.13302","volume":"169","author":"Y Suehiro","year":"2015","unstructured":"Suehiro Y, Hasegawa A, Iino T, Sasada A, Watanabe N, Matsuoka M, et al. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia\/lymphoma in a pilot study. Br J Haematol. 2015;169(3):356\u201367.","journal-title":"Br J Haematol"},{"issue":"9","key":"8289_CR71","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1182\/blood-2015-04-641118","volume":"126","author":"K Sugata","year":"2015","unstructured":"Sugata K, Yasunaga J-I, Mitobe Y, Miura M, Miyazato P, Kohara M, et al. Protective effect of cytotoxic T lymphocytes targeting HTLV-1 bZIP factor. Blood. 2015;126(9):1095\u2013105.","journal-title":"Blood"},{"issue":"2","key":"8289_CR72","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1399-3011.2003.00113.x","volume":"63","author":"R Sundaram","year":"2004","unstructured":"Sundaram R, Beebe M, Kaumaya PT. Structural and immunogenicity analysis of chimeric B-cell epitope constructs derived from the gp46 and gp21 subunits of the envelope glycoproteins of HTLV-1. J Pept Res. 2004;63(2):132\u201340.","journal-title":"J Pept Res"},{"issue":"3","key":"8289_CR73","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1097\/00126334-200411010-00001","volume":"37","author":"R Sundaram","year":"2004","unstructured":"Sundaram R, Lynch MP, Rawale S, Dakappagari N, Young D, Walker CM, et al. Protective efficacy of multiepitope human leukocyte antigen-A*0201 restricted cytotoxic T-lymphocyte peptide construct against challenge with human T-cell lymphotropic virus type 1 Tax recombinant vaccinia virus. J Acquir Immune Defic Syndr. 2004;37(3):1329\u201339.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"21\u201322","key":"8289_CR74","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1016\/S0264-410X(03)00179-8","volume":"21","author":"R Sundaram","year":"2003","unstructured":"Sundaram R, Sun Y, Walker CM, Lemonnier FA, Jacobson S, Kaumaya PT. A novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A*0201 transgenic mice: implications for HTLV-1 vaccine design. Vaccine. 2003;21(21\u201322):2767\u201381.","journal-title":"Vaccine"},{"issue":"10","key":"8289_CR75","doi-asserted-by":"publisher","first-page":"e0258443","DOI":"10.1371\/journal.pone.0258443","volume":"16","author":"MH Tariq","year":"2021","unstructured":"Tariq MH, Bhatti R, Ali NF, Ashfaq UA, Shahid F, Almatroudi A, et al. Rational design of chimeric Multiepitope Based Vaccine (MEBV) against human T-cell lymphotropic virus type 1: An integrated vaccine informatics and molecular docking based approach. PLoS One. 2021;16(10):e0258443.","journal-title":"PLoS One"},{"issue":"13\u201314","key":"8289_CR76","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.drudis.2009.04.001","volume":"14","author":"JC Tong","year":"2009","unstructured":"Tong JC, Ren EC. Immunoinformatics: current trends and future directions. Drug Discov Today. 2009;14(13\u201314):684\u20139.","journal-title":"Drug Discov Today"},{"issue":"3","key":"8289_CR77","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/vaccines7030088","volume":"7","author":"HA Dar","year":"2019","unstructured":"Dar HA, Zaheer T, Shehroz M, Ullah N, Naz K, Muhammad SA, et al. Immunoinformatics-Aided Design and Evaluation of a Potential Multi-Epitope Vaccine against Klebsiella Pneumoniae. Vaccines. 2019;7(3):88.","journal-title":"Vaccines"},{"key":"8289_CR78","first-page":"153","volume":"163","author":"JR Bennink","year":"1990","unstructured":"Bennink JR, Yewdell JW. Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function. Curr Top Microbiol Immunol. 1990;163:153\u201384.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"5986","key":"8289_CR79","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/311578a0","volume":"311","author":"JR Bennink","year":"1984","unstructured":"Bennink JR, Yewdell JW, Smith GL, Moller C, Moss B. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature. 1984;311(5986):578\u20139.","journal-title":"Nature"},{"issue":"11","key":"8289_CR80","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1128\/jvi.61.11.3416-3423.1987","volume":"61","author":"MK Spriggs","year":"1987","unstructured":"Spriggs MK, Murphy BR, Prince GA, Olmsted RA, Collins PL. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J Virol. 1987;61(11):3416\u201323.","journal-title":"J Virol"},{"issue":"4848","key":"8289_CR81","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1126\/science.2451288","volume":"240","author":"BD Walker","year":"1988","unstructured":"Walker BD, Flexner C, Paradis TJ, Fuller TC, Hirsch MS, Schooley RT, et al. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science (New York, NY). 1988;240(4848):64\u20136.","journal-title":"Science (New York, NY)"},{"key":"8289_CR82","doi-asserted-by":"publisher","first-page":"902478","DOI":"10.1155\/2014\/902478","volume":"2014","author":"T Ohashi","year":"2014","unstructured":"Ohashi T, Nakamura T, Kidokoro M, Zhang X, Shida H. Combined cytolytic effects of a vaccinia virus encoding a single chain trimer of MHC-I with a tax-epitope and tax-specific CTLs on HTLV-I-infected cells in a rat model. BioMed Res Int. 2014;2014:902478.","journal-title":"BioMed Res Int"},{"key":"8289_CR83","doi-asserted-by":"publisher","first-page":"1073779","DOI":"10.3389\/fimmu.2023.1073779","volume":"14","author":"CS Santana","year":"2023","unstructured":"Santana CS, Andrade FO, da Silva GCS, Nascimento JOS, Campos RF, Giovanetti M, et al. Advances in preventive vaccine development against HTLV-1 infection: A systematic review of the last 35 years. Front Immunol. 2023;14:1073779.","journal-title":"Front Immunol"},{"issue":"10","key":"8289_CR84","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.3390\/v14102084","volume":"14","author":"CA Pise-Masison","year":"2022","unstructured":"Pise-Masison CA, Franchini G. Hijacking Host Immunity by the Human T-Cell Leukemia Virus Type-1: Implications for Therapeutic and Preventive Vaccines. Viruses. 2022;14(10):2084.","journal-title":"Viruses"},{"key":"8289_CR85","doi-asserted-by":"publisher","first-page":"953650","DOI":"10.3389\/fimmu.2022.953650","volume":"13","author":"L Ratner","year":"2022","unstructured":"Ratner L. A role for an HTLV-1 vaccine? Front Immunol. 2022;13:953650.","journal-title":"Front Immunol"},{"key":"8289_CR86","doi-asserted-by":"publisher","first-page":"897346","DOI":"10.3389\/fmicb.2022.897346","volume":"13","author":"JJ Tu","year":"2022","unstructured":"Tu JJ, Maksimova V, Ratner L, Panfil AR. The Past, Present, and Future of a Human T-Cell Leukemia Virus Type 1 Vaccine. Front Microbiol. 2022;13:897346.","journal-title":"Front Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08289-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T11:04:04Z","timestamp":1683803044000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08289-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8289"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08289-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"assertion":[{"value":"11 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"320"}}